Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amgen, Inc. (AMGN), QUALCOMM, Inc. (QCOM): Investing in Growth Stocks — With Ease

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you’d like to add some growth stocks to your portfolio but don’t have the time or expertise to hand-pick a few, the Vanguard Growth ETF (NYSEARCA:VUG) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.

Amgen, Inc. (NASDAQ:AMGN)

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The Vanguard Growth ETF (NYSEARCA:VUG)’s expense ratio — its annual fee — is a very low 0.10%.

This ETF aspires to beat the S&P 500 soundly, but over the past three and five years, it has slightly underperformed and outperformed it, respectively. As with most investments, of course, we can’t expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why growth?
It’s smart to seek undervalued stocks, as value investors do. But it can also be appealing to add some “growth” stocks to your portfolio in the hope of juicing its overall performance. Growth stocks offer significant growth potential, and some of them are undervalued.

More than a handful of rapidly growing companies had strong performances over the past year. Gilead Sciences, Inc. (NASDAQ:GILD) surged 131%, for example, with investors hopeful about its oral hepatitis C drug, sofosbuvir, which has cleared four phase 3 trials and received priority-review designation from the FDA. The company has also been doing well with its HIV drugs in recent years, though sales of some have been flagging and competition looms. The stock may not look like a bargain with a P/E ratio in the 30s, but its five-year projected earnings growth rate is around 26%.

Biotech giant Amgen, Inc. (NASDAQ:AMGN) popped 42%. Bulls are excited about drugs in its pipeline that tackle melanoma and ovarian cancer, among other diseases. Amgen, Inc. (NASDAQ:AMGN) is also looking to acquire Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), which would bring with it more cancer treatments and success in getting drugs approved for multiple indications. (Others are eyeing Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) as well.) Some see Amgen, Inc. (NASDAQ:AMGN) now so big that it can’t grow as rapidly as its smaller biotech brethren. But it does offer a solid dividend yield of 1.8% and seems more attractively valued than many rivals.

QUALCOMM, Inc. (NASDAQ:QCOM), a top player in the smartphone world, gained 12%, supplying iDevices and Android devices alike with its chips.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.